Success Metrics

Active Trials
2(50%)

Phase Distribution

Ph phase_4
1
25%
Ph early_phase_1
3
75%

Phase Distribution

3

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Early Phase 1First-in-human
3(75.0%)
Phase 4Post-market surveillance
1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Other(2)

Detailed Status

unknown2
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
N/A
Most Advanced
Phase 4

Trials by Phase

Early Phase 13 (75.0%)
Phase 41 (25.0%)

Trials by Status

unknown250%
recruiting250%

Recent Activity

2 active trials
Showing 4 of 4
recruitingearly_phase_1

Losartan and Social Processing

NCT06624904
recruitingearly_phase_1

Losartan and Emotional Learning

NCT06628154
unknownearly_phase_1

Matão Controlling Hypertension (MatCH Study): Rationale and Design

NCT03147092
unknownphase_4

Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis

NCT02063100

Clinical Trials (4)

Showing 4 of 4 trials
NCT06624904Early Phase 1

Losartan and Social Processing

Recruiting
NCT06628154Early Phase 1

Losartan and Emotional Learning

Recruiting
NCT03147092Early Phase 1

Matão Controlling Hypertension (MatCH Study): Rationale and Design

Unknown
NCT02063100Phase 4

Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis

Unknown

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4